SCHEMBL4552086

SCHEMBL4552086

COC(=O)c1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.88
KDM4E B2RXH2 4/20 0.71
ALDH1A1 P00352 4/20 0.71
HPGD P15428 4/20 0.71
KMT2A Q03164 4/20 0.71
GLA P06280 3/20 0.71
GAA P10253 3/20 0.71
MEN1 O00255 3/20 0.71
MAPT P10636 3/20 0.71
CYP1A2 P05177 1/20 0.71
CYP2C19 P33261 1/20 0.71
GFER P55789 1/20 0.71
MAPK14 Q16539 4/20 0.70
MAPK13 O15264 3/20 0.70
MAPK12 P53778 3/20 0.70
MAPK11 Q15759 3/20 0.70
GCGR P47871 2/20 0.70
ALOX5 P09917 1/20 0.70
IDO1 P14902 1/20 0.67
NPC1 O15118 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31742329 0.92 RAF1 (0.76) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL30762099 0.92 RAF1 (0.76) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL12180841 0.86 RAF1 (0.68) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL8797140 0.86 RAF1 (0.67) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL14601534 0.85 RAF1 (0.66) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL2593317 0.84 KDM4E (0.91) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL19868984 0.84 MAPK14 (0.81) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL15071001 0.83 MAPK14 (0.63) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL2649978 0.83 MAPK14 (1.00) RAF1KDM4EALDH1A1HPGDKMT2A
SCHEMBL5943951 0.82 ALOX5 (0.70) RAF1KDM4EALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US claimed
EP-2015638-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF Redpoint Bio Corporation (US) 2009-01-21 EP disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 WO disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof TAS1R3, TAS2R1, TAS1R1 RAF1 963/4885KDM4E 3422/4885ALDH1A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.